» Articles » PMID: 39019054

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024

Abstract

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.

Citing Articles

Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma.

Huibers A, Leong S, Kashani-Sabet M, White Jr R, Vetto J, Schneebaum S Ann Surg Oncol. 2025; .

PMID: 40064798 DOI: 10.1245/s10434-025-17084-4.


Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer.

Cheng J, Kang W, Chen Y, Pan L, Han H, Lv T Cancer Immunol Immunother. 2025; 74(4):124.

PMID: 39998635 PMC: 11861770. DOI: 10.1007/s00262-025-03958-9.


Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat.

Resch E, Makri S, Ghanem P, Baraban E, Cohen K, Cohen A NPJ Precis Oncol. 2025; 9(1):48.

PMID: 39984702 PMC: 11845573. DOI: 10.1038/s41698-025-00826-8.


Management of Patients with Vulvar Cancers: A Systematic Comparison of International Guidelines (NCCN-ASCO-ESGO-BGCS-IGCS-FIGO-French Guidelines-RCOG).

Restaino S, Pellecchia G, Arcieri M, Bogani G, Taliento C, Greco P Cancers (Basel). 2025; 17(2).

PMID: 39857968 PMC: 11764181. DOI: 10.3390/cancers17020186.


Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review.

Borgognoni L, Susini P, Gerlini G, Brandani P, Giannotti V, Sestini S Cancers (Basel). 2025; 16(24.

PMID: 39766177 PMC: 11674682. DOI: 10.3390/cancers16244279.